Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 105 Neoplasms 11 Neoplasm Metastasis 11 Glioma 8 Ovarian Neoplasms 6 Melanoma 6 Glioblastoma 6 Squamous Cell Carcinoma of Head and Neck 5 Liposarcoma 5 Carcinoma, Non-Small-Cell Lung 5 Sarcoma 4 Recurrence 4 Medulloblastoma 4 Endometrial Neoplasms 4 Diffuse Intrinsic Pontine Glioma 4 Colorectal Neoplasms 4 Breast Diseases 4 Brain Neoplasms 4 Neuroblastoma 3 Neoplasms by Site 3 Lymphoma 3 Hereditary Sensory and Autonomic Neuropathies 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms, Male 3 Astrocytoma 3 Triple Negative Breast Neoplasms 2 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Fulvestrant 1 Epirubicin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × ribociclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡